| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 15,052.2 | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 15,052.2 | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 |
Other Operating Income | 209.5 | 559.9 | 0 | 0 | 0 |
Other Income | 1,304.7 | 865.5 | 375.9 | 212.7 | 267.1 |
Total Income | 16,566.4 | 15,621.2 | 11,550.1 | 8,396.7 | 7,410.2 |
Total Expenditure | 12,095.4 | 11,552.8 | 9,120.9 | 6,531.8 | 5,569.7 |
PBIDT | 4,471 | 4,068.4 | 2,429.2 | 1,864.9 | 1,840.5 |
Interest | 897.4 | 974.4 | 419 | 67.6 | 57.7 |
PBDT | 3,573.6 | 3,094 | 2,010.2 | 1,797.3 | 1,782.8 |
Depreciation | 1,687 | 1,568.8 | 1,113.1 | 814.2 | 715.1 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 389.2 | 314.3 | 353.3 | 211.5 | 221.5 |
Deferred Tax | 68 | -86.9 | -99.2 | 0 | 0 |
Reported Profit After Tax | 1,429.4 | 1,297.8 | 643 | 771.6 | 846.2 |
Minority Interest After NP | 416.1 | 275.3 | 180.3 | 123.2 | 105.7 |
Net Profit after Minority Interest | 1,013.3 | 1,022.5 | 462.7 | 648.4 | 740.5 |
Extra-ordinary Items | 73.11 | -9.21 | -176.64 | -87.2 | 9.99 |
Adjusted Profit After Extra-ordinary item | 940.19 | 1,031.71 | 639.34 | 735.6 | 730.51 |
EPS (Unit Curr.) | 8.46 | 8.55 | 3.88 | 5.44 | 6.24 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 25 | 10 | 30 | 10 | 0 |
Equity | 600.3 | 600.3 | 600.3 | 600.3 | 600 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 29.7 | 28.65 | 21.73 | 22.78 | 25.76 |
PBDTM(%) | 23.74 | 21.79 | 17.98 | 21.96 | 24.95 |
PATM(%) | 9.49 | 9.14 | 5.75 | 9.42 | 11.84 |
Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.
The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.
Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.
Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.
The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.
Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.
The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.
Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.
As per the company, YESINTEK shall be available in all the same formulations currently provided by Stelara.
Here are some of the stocks that may see significant price movement today: Biocon, NTPC Green Energy, LIC, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
